{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:16:49Z","timestamp":1790493409073,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Idelalisib, a selective PI3K\u03b4 inhibitor, has been approved by the FDA for chronic lymphocytic leukemia\/small lymphocytic lymphoma treatment and for follicular lymphoma treatment when combined with rituximab. However, the mechanisms of effective action of idelalisib in hepatocellular carcinoma (HCC) remain unclear. In the current study, we aimed to investigate how idelalisib inhibits the growth of HCC cells and enhances the effects of other chemotherapeutic drugs. Our results show that idelalisib treatment promotes Bim induction in HCC via the FoxO3a pathway following PI3K\/AKT inactivation. Moreover, our results show that Bim is required for idelalisib-mediated apoptosis in HCC. Idelalisib also synergizes with sorafenib or doxorubicin to induce significant apoptosis in HCC, and Bim is also necessary for the induction of apoptosis by cotreatment. Furthermore, a xenograft experiment reveals that the Bim deficiency abolishes apoptosis and antitumor effects of idelalisib in vivo. In summary, our results indicate a key role of Bim in mediating the antitumor effects of idelalisib in HCC. Our results also support the clinical significance of the drug.<\/jats:p>","DOI":"10.1038\/s41419-018-0960-8","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T11:48:17Z","timestamp":1537184897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["RETRACTED ARTICLE: Idelalisib promotes Bim-dependent apoptosis through AKT\/FoxO3a in hepatocellular carcinoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Dan","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"960_CR1","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.4254\/wjh.v7.i26.2648","volume":"7","author":"LP Waller","year":"2015","unstructured":"Waller, L. P., Deshpande, V. & Pyrsopoulos, N. Hepatocellular carcinoma: a comprehensive review. World J. Hepatol. 7, 2648\u20132663 (2015).","journal-title":"World J. Hepatol."},{"key":"960_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","volume":"16","author":"YA Ghouri","year":"2017","unstructured":"Ghouri, Y. A., Mian, I. & Rowe, J. H. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J. Carcinog. 16, 1 (2017).","journal-title":"J. Carcinog."},{"key":"960_CR3","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2, 16018 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"960_CR4","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3748\/wjg.v20.i15.4115","volume":"20","author":"A Raza","year":"2014","unstructured":"Raza, A. & Sood, G. K. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J. Gastroenterol. 20, 4115\u20134127 (2014).","journal-title":"World J. Gastroenterol."},{"key":"960_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.9738\/INTSURG-D-13-00122.1","volume":"99","author":"G Tsoulfas","year":"2014","unstructured":"Tsoulfas, G., Agorastou, P., Tooulias, A. & Marakis, G. N. Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. Int. Surg. 99, 779\u2013786 (2014).","journal-title":"Int. Surg."},{"key":"960_CR6","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2147\/OTT.S102573","volume":"9","author":"JC Barrientos","year":"2016","unstructured":"Barrientos, J. C. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco. Targets Ther. 9, 2945\u20132953 (2016).","journal-title":"Onco. Targets Ther."},{"key":"960_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"CY Cheah","year":"2016","unstructured":"Cheah, C. Y. & Fowler, N. H. Idelalisib in the management of lymphoma. Blood 128, 331\u2013336 (2016).","journal-title":"Blood"},{"key":"960_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007 (2014).","journal-title":"N. Engl. J. Med."},{"key":"960_CR9","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","volume":"39","author":"AS Weidner","year":"2015","unstructured":"Weidner, A. S. et al. Idelalisib-associated Colitis: Histologic Findings in 14 Patients. Am. J. Surg. Pathol. 39, 1661\u20131667 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"960_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson, B. L. et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128, 195\u2013203 (2016).","journal-title":"Blood"},{"key":"960_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Q Yang","year":"2015","unstructured":"Yang, Q., Modi, P., Newcomb, T., Queva, C. & Gandhi, V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin. Cancer Res. 21, 1537\u20131542 (2015).","journal-title":"Clin. Cancer Res."},{"key":"960_CR12","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.18632\/oncotarget.14043","volume":"8","author":"S Yang","year":"2017","unstructured":"Yang, S., Zhu, Z., Zhang, X., Zhang, N. & Yao, Z. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells. Oncotarget 8, 6102\u20136113 (2017).","journal-title":"Oncotarget"},{"key":"960_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","volume":"45","author":"L Ouyang","year":"2012","unstructured":"Ouyang, L. et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45, 487\u2013498 (2012).","journal-title":"Cell. Prolif."},{"key":"960_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/cc2950","volume":"9","author":"X Zhang","year":"2005","unstructured":"Zhang, X., Chen, Y., Jenkins, L. W., Kochanek, P. M. & Clark, R. S. Bench-to-bedside review: apoptosis\/programmed cell death triggered by traumatic brain injury. Crit. Care. 9, 66\u201375 (2005).","journal-title":"Crit. Care."},{"key":"960_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/cdd.2014.90","volume":"21","author":"MN Koenig","year":"2014","unstructured":"Koenig, M. N. et al. Pro-apoptotic BIM is an essential initiator of physiological endothelial cell death independent of regulation by FOXO3. Cell Death Differ. 21, 1687\u20131695 (2014).","journal-title":"Cell Death Differ."},{"key":"960_CR16","doi-asserted-by":"publisher","first-page":"a008714","DOI":"10.1101\/cshperspect.a008714","volume":"5","author":"A Shamas-Din","year":"2013","unstructured":"Shamas-Din, A., Kale, J., Leber, B. & Andrews, D. W. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008714 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"960_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/cdd.2017.170","volume":"25","author":"JT Opferman","year":"2018","unstructured":"Opferman, J. T. & Kothari, A. Anti-apoptotic BCL-2 family members in development. Cell Death Differ. 25, 37\u201345 (2018).","journal-title":"Cell Death Differ."},{"key":"960_CR18","first-page":"74","volume":"9","author":"P Hughes","year":"2006","unstructured":"Hughes, P., Bouillet, P. & Strasser, A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr. Dir. Autoimmun. 9, 74\u201394 (2006).","journal-title":"Curr. Dir. Autoimmun."},{"key":"960_CR19","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2006-11-056424","volume":"109","author":"M Chen","year":"2007","unstructured":"Chen, M., Huang, L. & Wang, J. Deficiency of Bim in dendritic cells contributes to overactivation of lymphocytes and autoimmunity. Blood 109, 4360\u20134367 (2007).","journal-title":"Blood"},{"key":"960_CR20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3892\/or.2015.4137","volume":"34","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26\/Ag85A-CD226 tumor cell vaccine. Oncol. Rep. 34, 1795\u20131804 (2015).","journal-title":"Oncol. Rep."},{"key":"960_CR21","doi-asserted-by":"publisher","first-page":"49795","DOI":"10.1074\/jbc.M309523200","volume":"278","author":"A Sunters","year":"2003","unstructured":"Sunters, A. et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278, 49795\u201349805 (2003).","journal-title":"J. Biol. Chem."},{"key":"960_CR22","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","volume":"24","author":"A Essafi","year":"2005","unstructured":"Essafi, A. et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24, 2317\u20132329 (2005).","journal-title":"Oncogene"},{"key":"960_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/sj.leu.2405098","volume":"22","author":"W Zhang","year":"2008","unstructured":"Zhang, W. et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22, 808\u2013818 (2008).","journal-title":"Leukemia"},{"key":"960_CR24","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3892\/or.2016.5176","volume":"36","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. Oncol. Rep. 36, 3643\u20133650 (2016).","journal-title":"Oncol. Rep."},{"key":"960_CR25","first-page":"2699","volume":"35","author":"GB Park","year":"2015","unstructured":"Park, G. B., Hur, D. Y. & Kim, D. Combining CAL-101 with celecoxib enhances apoptosis of EBV-transformed B-Cells through MAPK-induced ER stress. Anticancer Res. 35, 2699\u20132708 (2015).","journal-title":"Anticancer Res."},{"key":"960_CR26","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ejcb.2017.09.002","volume":"96","author":"S Shukla","year":"2017","unstructured":"Shukla, S., Saxena, S., Singh, B. K. & Kakkar, P. BH3-only protein BIM: An emerging target in chemotherapy. Eur. J. Cell Biol. 96, 728\u2013738 (2017).","journal-title":"Eur. J. Cell Biol."},{"key":"960_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cgt.2012.84","volume":"20","author":"LN Zhang","year":"2013","unstructured":"Zhang, L. N., Li, J. Y. & Xu, W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene. Ther. 20, 1\u20137 (2013).","journal-title":"Cancer Gene. Ther."},{"key":"960_CR28","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.bbamcr.2012.06.017","volume":"1823","author":"SM Ruppert","year":"2012","unstructured":"Ruppert, S. M. et al. The major isoforms of Bim contribute to distinct biological activities that govern the processes of autophagy and apoptosis in interleukin-7 dependent lymphocytes. Biochim. Biophys. Acta 1823, 1877\u20131893 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"960_CR29","doi-asserted-by":"publisher","first-page":"23058","DOI":"10.18632\/oncotarget.5492","volume":"6","author":"RV Sionov","year":"2015","unstructured":"Sionov, R. V., Vlahopoulos, S. A. & Granot, Z. Regulation of Bim in health and disease. Oncotarget 6, 23058\u201323134 (2015).","journal-title":"Oncotarget"},{"key":"960_CR30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.neo.2017.07.009","volume":"19","author":"YS Tu","year":"2017","unstructured":"Tu, Y. S. et al. The imipridone ONC201 induces apoptosis and overcomes chemotherapy resistance by upregulation of Bim in multiple myeloma. Neoplasia 19, 772\u2013780 (2017).","journal-title":"Neoplasia"}],"updated-by":[{"DOI":"10.1038\/s41419-024-07162-y","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"record-id":"58354"},{"DOI":"10.1038\/s41419-024-07162-y","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0960-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0960-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0960-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:58:17Z","timestamp":1730300297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0960-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["960"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0960-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"28 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-024-07162-y","URL":"https:\/\/doi.org\/10.1038\/s41419-024-07162-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"935"}}